Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01386632 · ClinicalTrials.gov registry record · Phase 2

Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma

A Phase 2 study, sponsored by Sanford Health.

Completed
Registry status
Phase 2
Development phase
50
Enrollment target

NCT01386632 is a Phase 2 study that has completed, run by Sanford Health. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01386632, a Phase 2 study, has completed, sponsored by Sanford Health.

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target

Study Summary

This will be a randomized masked placebo-controlled single-center study to evaluate the effects of Dichloroacetate (DCA) versus placebo given in combination with Cisplatin and radiation treatment in patients with Stage III-IV Squamous Cell Carcinoma of the Head and Neck (SCCHN). Fifty subjects will be enrolled and randomly assigned on a 1:1 ratio to DCA or matching placebo given with standard of care treatment consisting of Cisplatin and radiation treatment. Patients will receive DCA/placebo PO or per G-tube twice a day for 8 weeks. The first 6 patients of the total study population will represent a safety lead-in cohort. The results of the safety lead-in of DCA/placebo in combination with Cisplatin and radiation therapy will be evaluated after the 6th patient has completed 8 weeks of therapy. Recruitment of patients will be withheld during safety data analysis.

Interventions

  • DRUG Placebo
  • DRUG DCA (dichloroacetate)

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2011-05
Est. Completion 2020-06-01
Phase Phase 2

Sponsor

Sanford Health

34 total trials

What the Registry Record Tells You About NCT01386632

The ClinicalTrials.gov registry entry for NCT01386632 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanford Health, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01386632 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01386632 about?

NCT01386632 is a clinical study titled "Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma". This will be a randomized masked placebo-controlled single-center study to evaluate the effects of Dichloroacetate (DCA) versus placebo given in combination with Cisplatin and radiation treatment in patients with Stage III-IV Squamous Cell Carcinoma of the Head and Neck (SCCHN). Fifty subjects will ...

What is the current status of trial NCT01386632?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2011-05. Estimated completion is 2020-06-01.

What interventions are being tested in trial NCT01386632?

The interventions under investigation include: Placebo (DRUG), DCA (dichloroacetate) (DRUG).

Who is sponsoring clinical trial NCT01386632?

This trial is sponsored by Sanford Health, which has 34 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.